Sanofi broadens collaboration with Pieris

German independent, clinical-stage biotech firm Pieris AG and French drug major Sanofi (Euronext|: SAN) have jointly agreed to expand their ongoing discovery and development partnership to include a novel multi-specific Anticalin program.

Under the existing framework of the 2010 accord, the new program will entitle Pieris to an undisclosed upfront payment from Sanofi and committed research funding as well as payments for the achievement of research, preclinical, regulatory and commercial milestones. Specific financial terms were not disclosed.

“Following more than two years of successful collaboration in this multi-program agreement, the expansion demonstrates that the Anticalin technology can deliver key differentiation over conventional biologic approaches, including the development of multi-specific targeted therapeutics,” said Stephen Yoder, chief executive of Pieris, adding: “Sanofi and Pieris will continue to advance both existing and new programs, building on the excellent team chemistry between our organizations.”